NexImmune, Inc. announced a collaboration with the National Institute of Neurological Disorders and Stroke (NINDS), a division of the U.S. National Institutes of Health (NIH). The collaboration will focus on enriching and expanding virus-specific T cell populations and determining their activity against infected human cell lines. The goal of this collaboration is to develop adoptive cell therapies that may benefit patients afflicted with immunological disorders related to these viral infections.

Initially, will focus efforts on studying Epstein-Barr virus and Human T-cell Leukemia Virus, type 1 (HTLV-1).